← All organizations
Highest phase reached
Phase 4
First clinical trial
Feb 1, 2002First marketed drug
Nov 10, 2010First NDA
Nov 10, 2010Last known activity
Mar 4, 2021
Timeline
1990s
- Jan 1, 1993
Theratechnologies— Founded
2000s
- Jan 1, 2000
Pharma-G— Acquired
2010s
- Nov 10, 2010
tesamorelin— NDA Organization
- Mar 6, 2018
ibalizumab-uiyk— NDA Secondary Org
- Mar 6, 2018
ibalizumab-uiyk— Marketing Organization
Drugs by trial phase (2 distinct, 7 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Approved for
Marketed drugs (2)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (8)
- NCT04706962Lead sponsorPhase 1Mar 4, 2021
- NCT01591902Lead sponsorPhase 4Jun 1, 2012
- NCT01591902OfficialPhase 4Jun 1, 2012
- NCT01388920Lead sponsorPhase 2Sep 1, 2011
- NCT02012556Lead sponsorPhase 1May 1, 2008
- NCT00608023Lead sponsorPhase 3Aug 1, 2007
- NCT00123253Lead sponsorPhase 3Jun 1, 2005
- NCT01264497Lead sponsorPhase 2Feb 1, 2002
Details
- Founded
- Montreal, Quebec, CA Jan 1, 1993
- First NDA
- Nov 10, 2010
- Last known activity
- Mar 4, 2021
Notes
No evidence of NME R&D (rely upon existing products)